AstraZeneca Pharma India Limited has informed the bourses that it will launch Durvalumab (lmfinzi) in India on October 22, 2019.
The launch is referred in the communication dated June 21, 2018 as regards to the receipt of Import and Market Permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for Durvalumab (lmfinzi).
Durvalumab (lmfinzi) provides a treatment option for patients with locally advanced, unresectable Non-Small Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma.
Durvalumab (lmfinzi) is a product of AstraZeneca global. As of April 30, 2019, Durvalumab is approved in 18 countries for urothelial cancer and over 30 countries for NSCLC including US, EU, Japan and Brazil.
Last month, the company had received Import and Market permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets. FDC of Dapagliflozin 10mg + Saxagliptin 5mg is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM).
Both these drugs would strengthen the company’s product portfolio and its contribution in revenue would be seen by end of FY20.
On Tuesday, the stock of AstraZeneca opened at Rs. 2315. In the morning trading session, it surged 6.5 per cent to Rs. 2424 from its previous close of Rs. 2275.85. – DSIJ